Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors

  • Alba Rodriguez-Garcia
  • Keisuke Watanabe
  • Sonia GuedanEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 2086)


Animal models provide an essential tool to study the efficacy of CAR-T cell treatments. Most of the current works test human CAR-T cells in immunodeficient animals, typically NOD Scid Gamma (NSG) mice transplanted with human tumors. Despite the limitations of this model, including the difficulty to study the interaction between CAR-T cells and the human innate system and to assess the toxicity of this therapy, NSG are extensively used for adoptive T cell transfer studies. In this chapter, we will describe the protocols to test CAR-T cells in NSG animals with solid tumors. We first describe the implantation of human xenograft tumors in NSG animals, followed by CAR-T cell administration and assessment of antitumor responses. We will also review the protocols to analyze T cell persistence in the blood of treated animals. Finally, we will focus on the analysis of the tumors at the end point of the experiment, including the percentage, phenotype, and function of tumor infiltrating T cells, and loss of antigen expression.

Key words

Chimeric antigen receptors (CAR) Adoptive T cell transfer (ACT) NSG animals Tumor xenograft T cell persistence T cell exhaustion 


  1. 1.
    Morgan RA (2012) Human tumor xenografts: the good, the bad, and the ugly. Mol Ther 20(5):882–884CrossRefGoogle Scholar
  2. 2.
    Shultz LD, Goodwin N, Ishikawa F et al Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc 2014, 2014(7):694–708Google Scholar
  3. 3.
    Parihar R, Rivas C, Huynh M et al (2019) NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res 7(3):363–375CrossRefGoogle Scholar
  4. 4.
    Norelli M, Camisa B, Barbiera G (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24(6):739–748CrossRefGoogle Scholar
  5. 5.
    Giavridis T, van der Stegen SJC, Eyquem J (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24(6):731–738CrossRefGoogle Scholar
  6. 6.
    Sampson JH et al (2014) EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 20(4):972–984CrossRefGoogle Scholar
  7. 7.
    Mestas J, Hughes CCW (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172(5):2731–2738CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Alba Rodriguez-Garcia
    • 1
  • Keisuke Watanabe
    • 2
  • Sonia Guedan
    • 3
    Email author
  1. 1.Center for Cellular ImmunotherapiesPerelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Hematology and OncologyNagoya University Graduate School of MedicineNagoyaJapan
  3. 3.Department of Hematology and OncologyHospital Clinic, Institut d’Investigacions BiomÒdiques August Pi i Sunyer (IDIBAPS)BarcelonaSpain

Personalised recommendations